Jeffrey Richard Garber, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Nodule | 9 | 2023 | 764 | 2.580 |
Why?
|
| Endocrinology | 12 | 2021 | 442 | 1.660 |
Why?
|
| Hypothyroidism | 9 | 2016 | 668 | 1.610 |
Why?
|
| Thyroxine | 7 | 2016 | 666 | 0.930 |
Why?
|
| Thyroid Neoplasms | 8 | 2021 | 2332 | 0.880 |
Why?
|
| Thyroid Diseases | 4 | 2016 | 386 | 0.860 |
Why?
|
| Iodine Radioisotopes | 4 | 2013 | 1031 | 0.680 |
Why?
|
| Goiter, Substernal | 1 | 2014 | 17 | 0.470 |
Why?
|
| Disease Management | 3 | 2018 | 2508 | 0.420 |
Why?
|
| Jugular Veins | 1 | 2014 | 210 | 0.420 |
Why?
|
| Hypercalcemia | 2 | 2012 | 423 | 0.370 |
Why?
|
| Expert Systems | 1 | 2010 | 79 | 0.360 |
Why?
|
| Biopsy, Fine-Needle | 5 | 2021 | 1118 | 0.350 |
Why?
|
| Societies, Medical | 9 | 2018 | 3905 | 0.350 |
Why?
|
| Parathyroidectomy | 1 | 2012 | 242 | 0.340 |
Why?
|
| Thyroid Hormones | 4 | 2011 | 404 | 0.340 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2012 | 163 | 0.340 |
Why?
|
| Thyrotropin | 5 | 2016 | 834 | 0.340 |
Why?
|
| Sertraline | 2 | 2010 | 209 | 0.330 |
Why?
|
| Documentation | 1 | 2015 | 897 | 0.320 |
Why?
|
| Algorithms | 13 | 2023 | 14031 | 0.300 |
Why?
|
| Radiation Protection | 1 | 2012 | 424 | 0.300 |
Why?
|
| Conflict of Interest | 2 | 2010 | 554 | 0.300 |
Why?
|
| Adrenocortical Adenoma | 1 | 2008 | 46 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 6 | 2016 | 7390 | 0.300 |
Why?
|
| Thyroid Function Tests | 3 | 2016 | 288 | 0.290 |
Why?
|
| Authorship | 1 | 2010 | 284 | 0.270 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2008 | 161 | 0.270 |
Why?
|
| Vascular Diseases | 1 | 2014 | 1161 | 0.250 |
Why?
|
| Thyroxine-Binding Proteins | 1 | 2003 | 24 | 0.230 |
Why?
|
| Disclosure | 1 | 2010 | 748 | 0.230 |
Why?
|
| Drug Industry | 1 | 2010 | 788 | 0.220 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 2651 | 0.210 |
Why?
|
| Acclimatization | 1 | 2023 | 113 | 0.210 |
Why?
|
| Incidental Findings | 1 | 2008 | 697 | 0.210 |
Why?
|
| Physician's Role | 1 | 2010 | 917 | 0.210 |
Why?
|
| Triiodothyronine | 2 | 2016 | 493 | 0.210 |
Why?
|
| Electronics | 1 | 2023 | 318 | 0.200 |
Why?
|
| Computers | 1 | 2023 | 593 | 0.180 |
Why?
|
| Thyrotoxicosis | 2 | 2011 | 85 | 0.180 |
Why?
|
| Endocrine Surgical Procedures | 1 | 2020 | 32 | 0.180 |
Why?
|
| Guideline Adherence | 1 | 2010 | 2220 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2020 | 12148 | 0.170 |
Why?
|
| Ganglioneuroma | 1 | 1999 | 53 | 0.170 |
Why?
|
| Hyperthyroidism | 2 | 2011 | 294 | 0.160 |
Why?
|
| United States | 19 | 2023 | 72334 | 0.160 |
Why?
|
| Checklist | 2 | 2017 | 827 | 0.160 |
Why?
|
| Prolactinoma | 1 | 1999 | 114 | 0.160 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 1463 | 0.160 |
Why?
|
| Humans | 53 | 2023 | 761504 | 0.160 |
Why?
|
| Adenocarcinoma, Follicular | 2 | 2017 | 323 | 0.150 |
Why?
|
| Antidepressive Agents | 1 | 2010 | 2897 | 0.150 |
Why?
|
| Models, Educational | 1 | 2020 | 373 | 0.150 |
Why?
|
| Ultrasonography | 2 | 2021 | 5972 | 0.150 |
Why?
|
| Liver | 1 | 2013 | 7529 | 0.140 |
Why?
|
| Diet Therapy | 1 | 2018 | 151 | 0.140 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2016 | 43 | 0.130 |
Why?
|
| Graves Disease | 4 | 2011 | 238 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 9280 | 0.130 |
Why?
|
| Therapeutic Equivalency | 2 | 2006 | 134 | 0.130 |
Why?
|
| Thyroidectomy | 3 | 2020 | 907 | 0.120 |
Why?
|
| Heart Failure | 1 | 2019 | 11669 | 0.120 |
Why?
|
| Comprehensive Health Care | 1 | 2015 | 123 | 0.120 |
Why?
|
| Consensus | 6 | 2020 | 3123 | 0.110 |
Why?
|
| Otolaryngology | 1 | 2020 | 693 | 0.110 |
Why?
|
| Antithyroid Agents | 2 | 2011 | 72 | 0.110 |
Why?
|
| Receptors, Calcium-Sensing | 2 | 2012 | 318 | 0.100 |
Why?
|
| Ethics, Professional | 1 | 2012 | 100 | 0.100 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 588 | 0.100 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 785 | 0.100 |
Why?
|
| Culture | 1 | 2016 | 623 | 0.100 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 1117 | 0.100 |
Why?
|
| Whole Body Imaging | 1 | 2013 | 283 | 0.090 |
Why?
|
| Pituitary Neoplasms | 1 | 1999 | 1324 | 0.090 |
Why?
|
| Health Care Sector | 1 | 2012 | 195 | 0.090 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 751 | 0.090 |
Why?
|
| Constriction, Pathologic | 1 | 2014 | 1096 | 0.090 |
Why?
|
| Hypoglycemic Agents | 3 | 2018 | 3085 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2023 | 80636 | 0.090 |
Why?
|
| Radionuclide Imaging | 2 | 2013 | 1972 | 0.090 |
Why?
|
| Mass Screening | 2 | 2016 | 5428 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 2947 | 0.080 |
Why?
|
| Propylthiouracil | 1 | 2009 | 68 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2013 | 2265 | 0.080 |
Why?
|
| Societies, Scientific | 1 | 2009 | 222 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 495 | 0.080 |
Why?
|
| Medical Records | 1 | 2013 | 1408 | 0.070 |
Why?
|
| Thyroid Gland | 2 | 2013 | 1168 | 0.070 |
Why?
|
| Internet | 2 | 2023 | 3092 | 0.070 |
Why?
|
| Fluoxetine | 1 | 2010 | 733 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 990 | 0.070 |
Why?
|
| Prediabetic State | 3 | 2018 | 545 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2021 | 54425 | 0.070 |
Why?
|
| Oxyphil Cells | 1 | 2006 | 56 | 0.070 |
Why?
|
| Palpation | 1 | 2006 | 166 | 0.070 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2020 | 467 | 0.060 |
Why?
|
| Evidence-Based Medicine | 3 | 2012 | 3688 | 0.060 |
Why?
|
| Calcitonin | 1 | 2006 | 329 | 0.060 |
Why?
|
| Thymus Hyperplasia | 1 | 2005 | 32 | 0.060 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2006 | 148 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2008 | 793 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2005 | 274 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2010 | 1440 | 0.060 |
Why?
|
| Pregnancy | 6 | 2016 | 29874 | 0.060 |
Why?
|
| Legislation, Drug | 1 | 2005 | 214 | 0.050 |
Why?
|
| Blood Glucose | 4 | 2020 | 6391 | 0.050 |
Why?
|
| Endocrine System Diseases | 1 | 2005 | 249 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 5840 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 1505 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 4853 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2023 | 23995 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 1386 | 0.050 |
Why?
|
| Exercise | 1 | 2018 | 5890 | 0.050 |
Why?
|
| Life Style | 3 | 2018 | 3917 | 0.050 |
Why?
|
| United States Food and Drug Administration | 2 | 2009 | 1664 | 0.050 |
Why?
|
| Male | 10 | 2019 | 360804 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2013 | 10090 | 0.040 |
Why?
|
| Bromocriptine | 1 | 1999 | 93 | 0.040 |
Why?
|
| Synaptophysin | 1 | 1999 | 139 | 0.040 |
Why?
|
| Hormone Antagonists | 1 | 1999 | 107 | 0.040 |
Why?
|
| Female | 14 | 2016 | 392644 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 3201 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 857 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 15842 | 0.040 |
Why?
|
| 1-Naphthylamine | 1 | 1997 | 49 | 0.040 |
Why?
|
| Prolactin | 1 | 1999 | 625 | 0.040 |
Why?
|
| Neurofilament Proteins | 1 | 1999 | 336 | 0.040 |
Why?
|
| Insulin | 3 | 2016 | 6596 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 39106 | 0.030 |
Why?
|
| Costa Rica | 1 | 2016 | 180 | 0.030 |
Why?
|
| Adult | 10 | 2014 | 221177 | 0.030 |
Why?
|
| Triazines | 1 | 2018 | 311 | 0.030 |
Why?
|
| Latin America | 1 | 2016 | 410 | 0.030 |
Why?
|
| Physicians | 1 | 2012 | 4591 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 1008 | 0.030 |
Why?
|
| Preventive Medicine | 1 | 2016 | 246 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 842 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2003 | 2116 | 0.030 |
Why?
|
| Obesity | 4 | 2018 | 12947 | 0.030 |
Why?
|
| Reference Standards | 1 | 2017 | 1003 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 2822 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2018 | 609 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 771 | 0.030 |
Why?
|
| Codes of Ethics | 1 | 2012 | 61 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 635 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 2319 | 0.030 |
Why?
|
| Prognosis | 2 | 2016 | 29625 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 1999 | 1695 | 0.020 |
Why?
|
| Thyroid Crisis | 1 | 2011 | 8 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 10766 | 0.020 |
Why?
|
| Middle Aged | 6 | 2013 | 220895 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2016 | 879 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 41487 | 0.020 |
Why?
|
| Blood Pressure | 2 | 2016 | 8481 | 0.020 |
Why?
|
| Counseling | 1 | 2018 | 1547 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2020 | 3023 | 0.020 |
Why?
|
| Methimazole | 1 | 2009 | 41 | 0.020 |
Why?
|
| Calcium | 1 | 2003 | 5722 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 12974 | 0.020 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 11121 | 0.020 |
Why?
|
| Research Personnel | 1 | 2012 | 588 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 30052 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 823 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 1902 | 0.020 |
Why?
|
| Liver Failure | 1 | 2009 | 250 | 0.020 |
Why?
|
| Adolescent | 3 | 2011 | 88319 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2018 | 2056 | 0.020 |
Why?
|
| Publishing | 1 | 2012 | 833 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 1241 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 20570 | 0.010 |
Why?
|
| Total Quality Management | 1 | 2005 | 265 | 0.010 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 273 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 12128 | 0.010 |
Why?
|
| Comorbidity | 1 | 2018 | 10508 | 0.010 |
Why?
|
| Blood Physiological Phenomena | 1 | 2003 | 53 | 0.010 |
Why?
|
| Information Systems | 1 | 2005 | 396 | 0.010 |
Why?
|
| Inositol Phosphates | 1 | 2003 | 176 | 0.010 |
Why?
|
| Sleep | 1 | 2018 | 4768 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 3530 | 0.010 |
Why?
|
| Extracellular Space | 1 | 2003 | 563 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1988 | 1499 | 0.010 |
Why?
|
| Parathyroid Glands | 1 | 2003 | 518 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 1150 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1988 | 1189 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1988 | 1378 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2005 | 1243 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2003 | 853 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2003 | 551 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2005 | 1192 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2005 | 1315 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2020 | 15631 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2003 | 1125 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 1246 | 0.010 |
Why?
|
| Hypertension | 1 | 2018 | 8540 | 0.010 |
Why?
|
| Thyroglobulin | 1 | 1997 | 111 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2003 | 3597 | 0.010 |
Why?
|
| Medical Errors | 1 | 2005 | 1263 | 0.010 |
Why?
|
| Syndrome | 1 | 2003 | 3267 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 2003 | 1803 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 5035 | 0.010 |
Why?
|
| Pedigree | 1 | 2003 | 4542 | 0.010 |
Why?
|
| Time Factors | 2 | 2014 | 39967 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1997 | 1416 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1999 | 36426 | 0.010 |
Why?
|
| Communication | 1 | 2005 | 3873 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2003 | 5112 | 0.010 |
Why?
|
| Carcinoma | 1 | 2001 | 2330 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 15500 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 8529 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 15601 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 9000 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 6534 | 0.000 |
Why?
|
| Aged, 80 and over | 2 | 2005 | 58976 | 0.000 |
Why?
|
| Aged | 3 | 2005 | 169289 | 0.000 |
Why?
|
| Child | 1 | 2011 | 80153 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 14666 | 0.000 |
Why?
|
| Risk | 1 | 1988 | 9610 | 0.000 |
Why?
|